A A A

Institute News

Institute "fantastic" says Jeremy Hunt

Health secretary Jeremy Hunt met staff and patients on a visit to the Institute of Immunity and Transplantation, and descrbed its work as "just fantastic". Full story in the Ham and High.
More...

Institute open day: lab-grown organs, HIV vaccines, cure for cancer

The Institute's recent open day featured hands-on displays and demonstrations,  including 3-D printing of tissue-scaffolds for ear and nose replacement. Visitors chatted eagerly with scientists about their research, and heard presentations about ground-breaking work to develop new treatments for diseases including type-1 diabetes, cancer, scleroderma and hepatitis as well as HIV vaccines and artificial tissues and organs for transplantation.
More...

The latest trials and other clinical studies approved to take place via the Institute of Immunity and Transplantation:

Clinical trials and other patient-related studies

Well-being and kidney disease

ICECAP-O Version 1: A novel approach for assessment of wellbeing in older patients with end-stage kidney disease and their carers.
More...

Immune response to HBV vaccination

The adaptive immune response in hepatitis B vaccination.
More...

Respiratory illness in HIV

Acute respiratory tract illness in an HIV infected population with a high uptake of
antiretroviral therapy.
More...

Smoking and health

Health perceptions, smoking and health status More...

Management of advanced kidney disease

Multi-centre randomised controlled trial of angiotensin converting enzyme inhibitor (ACEi) / angiotensin receptor blocker (ARB) withdrawal in advanced renal disease.
More...

Axial spondyloarthritis clinical registry

Patients with axial spondyloaRthritis: multi-cOuntry registry OF clinical characteristics, including radiographic progression, and burden of disease over 5 years in real-life setting  (PROOF).
More...

HIV treatment in pregnancy

ING200336:   A prospective, interventional pharmacokinetic and safety study of DTG/ABC/3TC (dolutegravir/abacavir/lamivudine fixed dose combination) in pregnant women.
More...

Treatment switching in HIV

GS-US-311-1089:   A phase 3, randomized, double-blind, switch study to evaluate F/TAF in HIV 1 positive subjects who are virologically suppressed on regimens containing FTC/TDF.
More...

Steroids in influenza

Adjuvant steroids in adults with pandemic influenza (ASAP).
More...

Treatment of primary immunodeficiencies

A phase III, multicentre, open-label, randomised, two-period, crossover bioequivalence study to evaluate the pharmacokinetics, safety, and tolerability of Gammaplex 10 and Gammaplex 5% in primary immunodeficiency diseases.
More...

Treatment of systemic sclerosis

CSL Sclero XIII: A double-blind, randomized, placebo-controlled study to investigate pharmacokinetics (PK), safety and efficacy of intravenous factor XIII treatment in patients with systemic sclerosis.
More...

Bone turnover in haemodialysis patients

ALPHA- Defining normal bone turnover by mortality risk: a new look at bone alkaline phosphatase in haemodialysis patients. 
More...

Major surgery and anaemia

Preoperative intravenous iron to treat anaemia in major surgery (PREVENTT). More...

Kidney disease and the heart

SPIRO CKD: A randomised multicentre open label blinded end point trial to compare the effects of spironolactone to chlortalidone on left ventricular mass and arterial stiffness in stage 3 chronic kidney disease (CKD).
More...

Daily or weekly treatment for latent TB (HALT)

The HALT-LTBI study: Phase IV, multi-site, unblinded, randomised trial of prophylactic daily rifampicin/isoniazid vs. weekly rifapentine/isoniazid  for latent tuberculosis infection (LTBI).
More...

New treatment for psoriatic arthritis (CAIN)

CAIN: A phase III, randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab in autoinjectors, to demonstrate efficacy at 24 weeks and to assess the long term safety, tolerability and efficacy up to 3 years in subjects with active psoriatic arthritis.
More...

Rheumatoid arthritis treatment (SB5)

SB5: A Randomised, Double-blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Immunogenicity of SB5 Compared to Humira® in Subjects with Moderate to Severe Rheumatoid Arthritis despite Methotrexate Therapy.
More...

Patient-centred scleroderma management

The Scleroderma Patient-centered Intervention Network (SPIN) cohort.
More...

Intravenous iron in haemodialysis patients

PIVOTAL- UK multicentre open-label randomised controlled trial of IV iron therapy in incident haemodialysis patients.
More...

Cardiovascular risk in HIV patients

NEAT 22: An open label study examining the efficacy and cardiovascular risk of immediate versus deferred switch from a boosted PI to dolutegravir (DTG) in HIV infected patients with stable virological suppression.
More...

New treatments for lupus (SLE)

The use of novel biological therapies in the treatment of systemic lupus erythematosus (SLE). (BILAG)
More...

Management of stable chronic obstructive pulmonary disease

Effects of long term antibiotic therapy on exacerbation rate in stable COPD patients.
More...

Pulmonary arterial hypertension cohort study

National Cohort study of Idiopathic and Heritable Pulmonary Arterial Hypertension.
More...

Cardiovascular disease and TGF-beta superfamily

Isolation and characterisation of blood-derived progenitor cells in patients with cardiovascular disease and TGF-beta superfamily related diseases (Progenitor Study).
More...

Gastro-oesophageal reflux in scleroderma

Investigation into the role of gastro-oesophageal reflux  in Pulmonary Fibrosis in Scleroderma (GER Study).
More...

Page last modified on 06 feb 14 12:27